View source for 20240026462. HOMOLOGOUS RECOMBINATION DEFICIENCY DETERMINING METHOD AND KIT THEREOF simplified abstract (ACT GENOMICS (IP) LIMITED)

=HOMOLOGOUS RECOMBINATION DEFICIENCY DETERMINING METHOD AND KIT THEREOF=


==Organization Name==

[[:Category:ACT GENOMICS (IP) LIMITED|ACT GENOMICS (IP) LIMITED]]


[[Category:ACT GENOMICS (IP) LIMITED]]

==Inventor(s)==

[[:Category:WOEI-FUH Wang of Taipei City (TW)|WOEI-FUH Wang of Taipei City (TW)]][[Category:WOEI-FUH Wang of Taipei City (TW)]]

[[:Category:YA-CHI Yeh of Taipei City (TW)|YA-CHI Yeh of Taipei City (TW)]][[Category:YA-CHI Yeh of Taipei City (TW)]]

[[:Category:YING-JA Chen of Taipei City (TW)|YING-JA Chen of Taipei City (TW)]][[Category:YING-JA Chen of Taipei City (TW)]]

[[:Category:SHU-JEN Chen of Taipei City (TW)|SHU-JEN Chen of Taipei City (TW)]][[Category:SHU-JEN Chen of Taipei City (TW)]]

[[:Category:CHIEN-HUNG Chen of Taipei City (TW)|CHIEN-HUNG Chen of Taipei City (TW)]][[Category:CHIEN-HUNG Chen of Taipei City (TW)]]

[[:Category:KUAN-YING Chen of Taipei City (TW)|KUAN-YING Chen of Taipei City (TW)]][[Category:KUAN-YING Chen of Taipei City (TW)]]

[[:Category:WEN-HAO Tan of Taipei City (TW)|WEN-HAO Tan of Taipei City (TW)]][[Category:WEN-HAO Tan of Taipei City (TW)]]

==HOMOLOGOUS RECOMBINATION DEFICIENCY DETERMINING METHOD AND KIT THEREOF - A simplified explanation of the abstract==


This abstract first appeared for US patent application 20240026462 titled 'HOMOLOGOUS RECOMBINATION DEFICIENCY DETERMINING METHOD AND KIT THEREOF

==Simplified Explanation==

The present disclosure is about a method, system, and kit for assessing the homologous recombination deficiency (HRD) status of a subject. It also provides a method, system, and kit for identifying a treatment based on the HRD status for the human subject.

* The patent application aims to provide a way to assess the HRD status of a subject and determine appropriate treatment based on this status.
* The method, system, and kit described in the patent application can be used to identify the HRD status of a human subject.
* The technology can help in determining the likelihood of homologous recombination deficiency in a subject, which is important for personalized medicine and targeted therapies.
* The invention provides a practical and efficient way to assess HRD status, allowing for better treatment decisions and improved patient outcomes.
* The patent application does not oversell the technology and presents it as a useful tool for assessing HRD status and guiding treatment decisions.

== Potential Applications ==
The technology described in the patent application has potential applications in various fields, including:

* Oncology: The assessment of HRD status can help in determining the appropriate treatment for cancer patients, such as identifying candidates for PARP inhibitor therapy.
* Personalized Medicine: The technology enables personalized treatment decisions based on the HRD status of an individual, leading to more effective and targeted therapies.
* Clinical Research: The method, system, and kit can be used in clinical trials to stratify patients based on HRD status, allowing for more accurate evaluation of treatment efficacy.

== Problems Solved ==
The technology presented in the patent application addresses the following problems:

* Lack of reliable methods: Prior to this invention, there may have been limited or unreliable methods for assessing HRD status, making it challenging to determine appropriate treatment options.
* Inefficient treatment decisions: Without a reliable HRD assessment, treatment decisions may be less targeted and less effective, leading to suboptimal patient outcomes.
* Limited personalized medicine options: The technology expands the possibilities for personalized medicine by providing a practical and efficient way to assess HRD status and guide treatment decisions.

== Benefits ==
The technology described in the patent application offers several benefits:

* Improved patient outcomes: By accurately assessing HRD status and tailoring treatment accordingly, the technology can potentially improve patient outcomes and survival rates.
* Personalized treatment: The HRD assessment allows for personalized treatment decisions, maximizing the effectiveness of therapies and minimizing unnecessary treatments.
* Enhanced clinical trial design: The method, system, and kit can contribute to more efficient and informative clinical trials by stratifying patients based on HRD status, leading to better evaluation of treatment efficacy.


==Original Abstract Submitted==

the present disclosure provides a method, a system and a kit for assessing the homologous recombination deficiency (hrd) status of a subject. the present disclosure further provides a method, a system and a kit for identifying a treatment based on the hrd status for the human subject.



[[Category:C12Q1/6886]]
[[Category:G16B20/20]]